ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
2.005
-0.025 (-1.23%)
May 18, 2026, 10:35 AM EDT - Market open
ALX Oncology Holdings Employees
ALX Oncology Holdings had 43 employees as of December 31, 2025. The number of employees decreased by 37 or -46.25% compared to the previous year.
Employees
43
Change
-37
Growth
-46.25%
Revenue / Employee
n/a
Profits / Employee
-$2,066,698
Market Cap
269.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 43 | -37 | -46.25% |
| Sep 30, 2025 | 44 | -45 | -50.56% |
| Jun 30, 2025 | 49 | -32 | -39.51% |
| Mar 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 80 | 8 | 11.11% |
| Sep 30, 2024 | 89 | 18 | 25.35% |
| Jun 30, 2024 | 81 | 9 | 12.50% |
| Mar 31, 2024 | 74 | 9 | 13.85% |
| Dec 31, 2023 | 72 | 14 | 24.14% |
| Sep 30, 2023 | 71 | 16 | 29.09% |
| Jun 30, 2023 | 72 | 20 | 38.46% |
| Mar 31, 2023 | 65 | 21 | 47.73% |
| Dec 31, 2022 | 58 | 15 | 34.88% |
| Sep 30, 2022 | 55 | 23 | 71.88% |
| Jun 30, 2022 | 52 | 23 | 79.31% |
| Mar 31, 2022 | 44 | 20 | 83.33% |
| Dec 31, 2021 | 43 | 20 | 86.96% |
| Sep 30, 2021 | 32 | 15 | 88.24% |
| Jun 30, 2021 | 29 | 10 | 52.63% |
| Mar 31, 2021 | 24 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| AC Immune | 122 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| Silence Therapeutics | 88 |
| Editas Medicine | 87 |
| SAB Biotherapeutics | 86 |
| Compugen | 75 |
ALXO News
- 10 days ago - ALX Oncology Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 10 days ago - ALX Oncology evorpacept combination data presented at ESMO congress - TheFly
- 11 days ago - ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression - GlobeNewsWire
- 18 days ago - ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026 - GlobeNewsWire
- 4 weeks ago - ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 5 weeks ago - ALX Oncology appoints Jeff Knight as chief development, operating officer - TheFly
- 5 weeks ago - ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer - GlobeNewsWire